Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC.

(EXEL)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2019 02/15/2019 02/19/2019 02/20/2019 02/21/2019 Date
22.3(c) 22.26(c) 21.35(c) 21.24(c) 21.22(c) Last
5 323 668 4 092 050 4 847 267 3 957 368 2 082 281 Volume
+1.13% -0.18% -4.09% -0.52% -0.09% Change
More quotes
Financials (USD)
Sales 2019 949 M
EBIT 2019 377 M
Net income 2019 318 M
Finance 2019 1 349 M
Yield 2019 -
Sales 2020 1 159 M
EBIT 2020 476 M
Net income 2020 428 M
Finance 2020 1 721 M
Yield 2020 -
P/E ratio 2019 21,07
P/E ratio 2020 15,79
EV / Sales2019 5,26x
EV / Sales2020 3,99x
Capitalization 6 344 M
More Financials
Company
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF... 
More about the company
Surperformance© ratings of Exelixis, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on EXELIXIS, INC.
02/21EXELIXIS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year..
AQ
02/12EXELIXIS, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
02/12EXELIXIS : 4Q Earnings Snapshot
AQ
02/12EXELIXIS : Announces Fourth Quarter and Full Year 2018 Financial Results and Pro..
BU
02/12EXELIXIS : to Initiate Phase 1 Clinical Development of XL092, First New Compound..
BU
02/08EXELIXIS : to Present at the Guggenheim Healthcare Talks Idea Forum, Oncology Da..
AQ
02/07EXELIXIS : to Present at the Guggenheim Healthcare Talks Idea Forum / Oncology D..
BU
02/07EXELIXIS, INC. : annual earnings release
01/29EXELIXIS : to Release Fourth Quarter and Full Year 2018 Financial Results on Tue..
BU
01/17EXELIXIS : enters crowded liver cancer field with Cabometyx, taking on Bayer, BM..
AQ
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Stock Trading Strategies
EXELIXIS, INC. - 01/15
Buying pressure
BUY
More Stock Trading Analysis
Sector news : Bio Therapeutic Drugs
02/20GLOBAL MARKETS LIVE : Nissan, Lockheed Martin, UBS, Sainsbury...
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06REGENERON PHARMACEUTICALS : 4Q Profit Rises
DJ
More sector news : Bio Therapeutic Drugs
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 28,2 $
Spread / Average Target 33%
EPS Revisions
Managers
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Chief Financial & Accounting Officer, Executive VP
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.7.98%6 344
GILEAD SCIENCES6.73%86 647
VERTEX PHARMACEUTICALS13.49%48 023
REGENERON PHARMACEUTICALS13.51%45 363
GENMAB-5.57%9 415
SAREPTA THERAPEUTICS INC25.12%9 393